Coverage: 64 pre-commercial assets
Concentration: Oncology
Issue No. 19 · May 2026
Stage I

Capture

Every pre-commercial biotechnology company within the coverage universe is monitored continuously across a defined set of public sources. Each source is checked on a regular cycle, and every relevant event — a regulatory filing, a personnel change, a trial update — is recorded, dated, and attributed.

The objective at this stage is completeness, not interpretation. A signal that is captured late is a signal that arrives after the engagement window has closed.

SEC EDGAR
Registration statements, quarterly and annual reports, and current event disclosures. The primary source for commercial spend signals and corporate transitions.
FDA ACTION CALENDAR
PDUFA dates, advisory committee scheduling, and designation announcements. Establishes the regulatory timeline against which all other signals are measured.
CLINICALTRIALS.GOV
Trial status, completion, and readout activity. Confirms the clinical position of each asset and forward catalyst timing.
PERSONNEL RECORDS
Public hiring activity and executive transitions. Commercial leadership appointments are among the most reliable indicators of launch sequencing.
EARNINGS DISCLOSURES
Quarterly call transcripts and financial statements. Commercial infrastructure spending is visible in general and administrative expense trends.
CONFERENCE & KOL ACTIVITY
Scientific conference participation and key opinion leader engagement. Indicates medical affairs readiness and market preparation.
Stage II

Interpretation

A captured event is not yet intelligence. A Chief Commercial Officer appointment is a fact; what that fact implies depends entirely on who is asking. For a contract sales organization it signals the approach of a field force decision. For a patient hub services provider it signals a forthcoming procurement cycle. The same event, interpreted twice.

Each asset is assessed across approximately twelve signal categories. The categories are stable; the interpretation is specific to the asset, its indication, its competitive context, and the service provider for whom the brief is prepared.

01 — 04
Regulatory position
Filing status, review designation, action date, and advisory committee exposure.
05 — 07
Commercial buildout
Leadership appointments, field and medical hiring velocity, and infrastructure spend.
08 — 09
Market structure
Call universe sizing, competitive landscape, and displacement opportunity.
10 — 12
Engagement window
Decision-maker mapping, procurement timing, and recommended sequencing.
Stage III

Delivery

Intelligence that arrives without structure is not acted upon. Each subscriber receives a standing weekly brief covering the highest-relevance accounts within their chosen scope — a defined number of assets, each presented on a single page, each with the underlying signal, the relevant decision-maker, and a recommended next step.

The brief is designed to be read in minutes and acted upon the same day. It does not require the subscriber to conduct further research. That is the point of the work.

Operating principle

The value of a signal is a function of how early it arrives and how clearly it states the action it implies.

Stage IV

Facilitation

Intelligence identifies the opportunity. It does not, by itself, secure the engagement. Where a subscriber elects, Nexus Signal extends beyond the brief: identifying the relevant decision-maker, establishing the appropriate point of contact, and supporting the introduction itself.

This is the distinction at the centre of the work. A subscriber does not pay for information they could, in principle, assemble themselves. They engage Nexus Signal to compress the months between knowing and acting — and to arrive in the room before the window closes.

The scope of facilitation is defined per engagement. It is described in full during an introductory conversation.

On Scope

What this work is not.

Nexus Signal provides commercial intelligence to service providers. It does not provide investment advice, securities research, or trading recommendations of any kind, and it does not engage with investment firms or any party employing its intelligence for securities trading decisions.

The intelligence is interpretive and operational. It concerns the timing of commercial vendor engagement — not the valuation of a security. All sources are public. No privileged or non-public information is used at any stage of the process.

The method is straightforward. The discipline is the difference.

An introduction begins with a twenty-minute conversation and an indicative brief on an account of your selection.